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Santiago, Chile, and Brescia, ItalyBackground: Cartilage-hair hypoplasia (CHH) is characterized
by metaphyseal dysplasia, bone marrow failure, increased risk of
malignancies, and a variable degree of immunodeficiency. CHH is
caused by mutations in the RNA component of the mitochondrial
RNAprocessing (RMRP) endoribonuclease gene, which is involved
in ribosomal assembly, telomere function, and cell cycle control.
Objectives: We aimed to define thymic output and characterize
immune function in a cohort of patients with molecularly
defined CHH with and without associated clinical
immunodeficiency.
Methods: We studied the distribution of B and T lymphocytes
(including recent thymic emigrants), in vitro lymphocyte
proliferation, cell cycle, and apoptosis in 18 patients with CHH
compared with controls.
Results: Patients with CHH have a markedly reduced number
of recent thymic emigrants, and their peripheral T cells show
defects in cell cycle control and display increased apoptosis,
resulting in poor proliferation on activation.
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Cartilage-hair hypoplasia (CHH) is a rare autosomal recessive
syndrome, characterized by metaphyseal dysplasia, hypoplastic
hair, bone marrow failure, immunodeficiency, and an increased
risk of Hirschsprung disease and malignancies.1,2 A variable de-
gree of immunodeficiency has been reported in CHH that predom-
inantly affects T-lymphocyte number and function. A minority of
patients with CHH present with combined immunodeficiency.3,4
Hematopoietic cell transplantation is the treatment of choice in
these cases.5,6 Recently, a case of antibody deficiency resembling
common variable immune deficiency has been identified in an
adult patient with CHH.7
Cartilage-hair hypoplasia is caused by mutations of the RMRP
gene,8which encodes for theRNAcomponent of themitochondrial
RNA processing (RMRP) endoribonuclease complex that cleaves
the precursor ribosomal RNA and contributes to ribosome biogen-
esis.9 In yeast, RMRP regulates cell cycle. RMRPmutations in hu-
man beings result in decreased levels of cyclin B2 mRNA10 and
may result in chromosomal instability. Finally, recent data indicate
that RMRP also forms a complex with the telomerase reverse tran-
scriptase catalytic subunit,11 raising the possibility that telomere
dysfunction is part of the cellular phenotype of the disease.
The cellular mechanisms underlying the immunodeficiency of
CHH have remained poorly characterized, also because of the
lack of animal models. It has been demonstrated that T cells show
reduced secretion of IL-2 and IFN-g after activation in vitro and
enhanced apoptosis, associated with increased expression of
proapoptotic molecules.12,13 Furthermore, severe abnormalities
of thymic architecture have been described in patients with com-
bined immunodeficiency (CID) caused by RMRP mutations4,14;
however, no data are available on thymic function in patients
with CHHwho do not have clinical features of immunodeficiency.
Here, we present data on recent thymic emigrants (RTEs),
in vitro T-lymphocyte proliferation, cell cycle, and apoptosis in 18
patients with typical features of CHH, well defined RMRP muta-
tions, and a variable degree of immunodeficiency. Our data indi-
cate that lymphocyte abnormalities are an integral component of
CHH, reflecting the role of RMRP in cellmetabolismand function.139
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140 DE LA FUENTE ET ALAbbreviations used7-AAD: 7-Aminoactinomycin DAnnV: Annexin VBrdU: BromodeoxyuridineCFSE: Carboxyfluorescein diacetate succinimidyl esterCHH: Cartilage-hair hypoplasiaCID: Combined immunodeficiencycpm: Counts per minuteEdU: 5-Ethynyl-2-deoxyuridineHCT: Hematopoietic cell transplantationhrIL-2: Human recombinant IL-2RMRP: RNA component of the mitochondrial RNA processingRTE: Recent thymic emigrantSI: Stimulation indexMETHODS
Patients
Eighteen subjects with typical features of CHH (skeletal and hair abnor-
malities) were included in the study (mean age, 10.9 years; range, 1.0-21.0
years). Of these, 13 belonged to the Amish population in Pennsylvania.
Deidentified information on clinical history was obtained for all patients from
the referring physicians. Blood was collected from patients and controls by
venipuncture. Informed consent was obtained from patients and parents in
accordance with the local Institutional Review Board at Hershey Medical
Center and Children’s Hospital Boston, Mass.
A 21-year-old patient was included in the group 15 to 18 years old because
no normal values were available for ages >18 years.15
Patients were classified into different clinical subsets as shown in Table I:
(1) CHHwithout a history of infections, (2) CHHwith infections, and (3) CHH
with CID.
All patients had a confirmed mutation in the RMRP gene. For this purpose,
genomic DNAwas extracted from blood samples in EDTA by using standard
procedures and was analyzed by PCR amplification and direct sequencing of
the RMRP gene as previously described.3 In the case of patient 18, who was a
compound heterozygote for a genomic insertion, the PCR fragments were
cloned into a TOPO-TA cloning vector (Invitrogen, Paisley, United Kingdom).
At least 10 single colonies were picked and sequenced.
Fluorescence-activated cell sorting analysis of
lymphocyte subpopulations
PBMCs were separated by Ficoll gradient (Ficoll Histopaque 1077;
Sigma-Aldrich, St Louis, Mo), counted, and stained with combinations
of the following mAbs: CD3-APC/CD19-PERCP-CY5.5/IgD-fluorescein
isothiocyanate/CD27-phycoerythrin, CD4 PERCPCY5.5/CD45RA fluores-
cein isothiocyanate/CD8APC/CD31 phycoerythrin (all fromBDBiosciences,
San Jose, Calif). Analysis of lymphocyte subsets was performed by 4-color
flow cytometry using FACS Calibur (BD Biosciences). Data were analyzed by
using FlowJo software (Tree Star, Ashland, Ore).
Lymphocyte proliferation
PBMCs were labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE; Molecular Probes, Eugene, Ore), 5 mmol/L final concentration in
PBS1 0.1% BSA for 5 minutes at 37 degrees. Cells were then washed twice
with RPMI 10% FCS and cultured for 72 hours in the absence or presence of
100 ng/mL anti-CD3 (clone OKT3; eBioscience, San Diego, Calif) with or
without 20 ng/mL human recombinant IL-2 (hrIL-2; Roche Applied Biosci-
ence, Mannheim, Germany). Fluorescence-activated cell sorting analysis was
performed by 4-color analysis on a FACS Calibur (BD Biosciences).
Proliferation to PHA was assessed by culturing PBMCs with PHA (10 mg/
mL final concentration) for 72 hours, followed by measuring tritiated
thymidine (3[H]TdR) incorporation as counts per minute (cpm). Results
were expressed as the stimulation index (SI), as follows:SI 5 ½cpmðPHAÞ 2 ½cpmðmediumÞ = ½cpmðmediumÞ:
Cell cycle and cell death analysis
PBMCs (prepared and stimulated for 96 hours as described with anti-CD3,
with or without IL-2) were labeled with bromodeoxyuridine (BrdU; BD
Biosciences) or with 5-ethynyl-2-deoxyuridine (EdU Click-It kit; Invitrogen,
Carlsbad, Calif), according to the manufacturers’ instructions.
For analysis of cell death, in vitro cultured PBMCswere stained for Annexin
V (AnnV; eBioscience, San Diego, Calif; or BD Biosciences) and 7-aminoac-
tinomycin D (7-AAD; eBioscience) in AnnV buffer for 30 minutes at room
temperature.
Samples were analyzed by 4-color flow cytometry using a FACS Calibur
(BD Biosciences).RESULTS
Description of the clinical phenotype and genotype
We analyzed a cohort of 18 patients with clinical diagnosis of
CHH and genetically confirmed RMRP mutations. Clinical fea-
tures of a subgroup of the patients analyzed here were previously
described in an Amish CHH cohort.16 Individual data on the clin-
ical phenotypes are reported in Table I. Eleven patients had a his-
tory of severe and/or recurrent infections (n 5 11), chronic
diarrhea (n 5 2), cytopenias (n 5 3), and/or autoimmunity
(n 5 1). Three of these 11 patients had a clinical phenotype of
CID (Table I). Seven patients did not have a significantly in-
creased incidence of infections. All patients from the Amish com-
munity (patients 1-13) were homozygous for the common
g.A70>Gmutation. In addition, the g.C217>Tand g.A118>Gmu-
tations (identified in patients 14 and 15, respectively) had also
been previously reported in patients with CHH.10 In contrast,
the g.G18>C, the g.G27>A, and the g.G61>A nucleotide changes
(identified in patients 15, 17, and 18, respectively) represent novel
mutations. Moreover, in patient 18, we found a duplication lo-
cated in the region between the TATA box and the transcription
initiation site (-23-8dupTACTCTGTGAAGCTGAG).Analysis of lymphocyte subsets
Analysis of the immunologic phenotype showed that patients’
absolute total CD31, CD41, and CD81 T lymphocyte numbers
were low or at the lower range of normal comparedwith published
control values for an age-matched healthy pediatric population15
(Fig 1; mean age, 10.9 years; range, 1.0-21.0 years). In most pa-
tients, the absolute number of circulating CD191 B lymphocytes
was at the lower range of normal, but the relative proportions of
IgD-CD271 switched memory CD191 B cells and of
IgD1CD271 (mostly marginal zone–like) B cells appeared com-
parable towhat was observed in healthy controls (Fig 1). To define
whether the observed T-cell lymphopeniawas secondary to defec-
tive thymopoiesis, we evaluated the absolute and relative number
of CD41CD45RA1CD311 RTE cells. As shown in Fig 2, both
the absolute and relative numbers of RTEs were significantly re-
duced in the patients with CHH, regardless of their age, compared
with published normal values.15Analysis of T-cell activation and proliferation
in vitro
To define whether the T-cell lymphopenia observed in patients
with CHH might also reflect impaired cell proliferation, we
TABLE I. Clinical and molecular features of the patients
Patient no. Age (y) Sex Mutation Clinical history Diagnosis
1 10.0 F g.70A>G; g.70A>G No infections CHH, no infections
2 12.0 F g.70A>G; g.70A>G Parvovirus infection, juvenile arthritis CHH 1 infections
3 2.5 F g.70A>G; g.70A>G Interstitial pneumonia CHH 1 infections
4 1.0 M g.70A>G; g.70A>G Recurrent URTI CHH 1 infections
5 3.9 F g.70A>G; g.70A>G No infections CHH, no infections
6 5.8 M g.70A>G; g.70A>G No infections CHH, no infections
7 7.7 M g.70A>G; g.70A>G No infections CHH, no infections
8 3.7 M g.70A>G; g.70A>G No infections CHH, no infections
9 21.0 F g.70A>G; g.70A>G Recurrent URTI CHH 1 infections
10 15.0 F g.70A>G; g.70A>G Sepsis CHH 1 infections
11 6.7 F g.70A>G; g.70A>G No infections CHH, no infections
12 5.0 F g.70A>G; g.70A>G Pneumonia CHH1 infections
13 9.0 F g.70A>G; g.70A>G No infections CHH, no infections
14 7.0 F g.70A>G; g.217C>T Recurrent URTI, chronic diarrhea CHH 1 CID
15 5.0 M g.18G>C; g.118A>G Recurrent URTI, molluscum CHH 1 infections
16 2.0 F g.70A>G; g.70A>G Sepsis CHH 1 infections
17 11.7 M g.27G>A; g.27G>A Aspergillus and CMV pneumonia,
EBV-related lymphoproliferation
CHH 1 CID
18 2.0 M g.61G>A; g.-23_8dup
TACTCTGTGAAGCTGAG
Sepsis, recurrent pneumonia CHH 1 CID
CMV, Cytomegalovirus; F, female; M, male; URTI, upper respiratory tract infection.
FIG 1. Lymphocyte subpopulations. In each panel, the shaded areas correspond to the value range of
healthy control children from the various age groups.15
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Fig 3, the majority of individuals with CHH tested had a dimin-
ished response to PHA, with SI values that were below the lower
range for normal controls (SI 5 60). PHA responses in patients
with CHH and infection were significantly lower than in patients
without infections. We also measured proliferation ofCFSE-labeled PBMCs on stimulation in vitro with anti-CD3 ag-
onistic antibodies in the presence or absence of hrIL-2. As
shown in Fig 4, proliferation of CD31 lymphocytes from pa-
tients with CHH was impaired. In particular, under stronger
(anti-CD31IL-2) activating conditions, the percentage of
CD31 lymphocytes that did not initiate cell division was
FIG 2. RTEs. The absolute (A) and relative (B) number of RTEs (CD41CD45RA1CD311) in patients with CHH
was plotted against the value range of healthy pediatric controls for various age groups.15
FIG 3. T-cell proliferation in response to PHA. Values are expressed as SI. The dashed line at SI 5 60 repre-
sents the lower range of PHA response in healthy individuals.
J ALLERGY CLIN IMMUNOL
JULY 2011
142 DE LA FUENTE ET ALsignificantly higher among patients with CHH (mean 6 SD,
69.4 6 18.7) than in controls (45.3 6 19.3; P < .05). Some
but not absolute correlation was observed between the degree
of impairment of T-cell proliferation and the severity of the clin-
ical phenotype.Analysis of cell cycle
RMRP has been shown to play a key role in cell cycle control.
Deficiency of the RMRP homolog non-metastatic cells 1 (nme1)
gene in yeast causes accumulation of cyclin B2 mRNA and delay
in cell-cycle progression.17 Similar findings have been reported in
fibroblasts from patients with CHH, along with reduced levels of
cyclin A2.10 We evaluated the impact of RMRPmutations on cell
cycle in T lymphocytes as a possible contributory factor to the im-
munodeficiency in CHH. For this purpose, we stimulated PBMCs
in vitrowith agonistic anti-CD3 mAb (in the presence or absence
of hrIL-2), followed by addition of BrdU/EdU. To assess the dis-
tribution of cells at various phases during the cell cycle, we used
flow cytometry and analyzed BrdU/EdU incorporation in combi-
nation with staining for the DNA binding dye 7-AAD, which per-
mits definition of cell ploidy. Using this method, it was possible todistinguish cells that were in G0/G1 phase (BrdU– 7-AADlo), syn-
thesis (S phase; BrdU17-AADlo/hi), or G2/M phase (BrdU–
7-AADhi). As shown in Fig 5, on in vitro stimulation with
anti-CD3, patients with CHH had an increased proportion of cells
in the G2/M phase (mean 6 SD, 12.8 6 5.7 vs 7.4 6 6.7 in pa-
tients vs controls; P <.05). An increase of cells in the G2/M phase
was also observed in lymphocytes of patients with CHH on stim-
ulation with anti-CD31 IL-2, although it did not reach statistical
significance, and was associated with a marked decrease of lym-
phocytes in S phase (mean6 SD, 31.16 11.2 vs 45.16 11.1 for
patients vs controls; P < .05). The reduced proportion of cells
entering S phase and the prolongation of the cell cycle (with a
higher proportion of cells in the G2/M phase) are consistent
with the reduced number of cell divisions and the defective
T-cell proliferation reported.Increased activation-induced cell death in
patients CHH
Increased T-cell apoptosis has been previously reported in
1 patient with CHH13 but has not been further investigated. We
have analyzed activation-induced apoptosis in lymphocytes
FIG 4. T-cell proliferation in response to agonistic anti-CD3 antibody. Left, Representative examples of
proliferation of control-derived or patient-derived PBMCs in response to anti-CD3 (top) or anti-CD3 1 IL-2
(bottom), as measured by CFSE dilution of CD31 cells. Boxes identify different rounds of proliferation,
and the proportion of cells within each box is annotated. Gating was done on viable cells. Right, Proportion
of PBMCs undergoing 0 to 1 or >_2 rounds of cell division in response to anti-CD3 (top) or anti-CD3 1 IL-2
(bottom). Individual symbols identify single subjects. In each diagram, the horizontal bar represents the
mean value. *P < .05.
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anti-CD3 mAb in the presence or absence of IL-2. We used
flow cytometry by simultaneously staining the cells for AnnV
and for incorporation of 7-AAD. This method allows identifica-
tion of viable (AnnV– 7-AAD–), early apoptotic (AnnV1
7-AAD–), and late apoptotic/necrotic (AnnV1 7-AAD1) cells.
As shown in Fig 6, the percentage of both early and late apoptotic
cells was increased in patients with CHH versus healthy controls,
reaching a statistically significant difference for late apoptotic/ne-
crotic cells on culture with anti-CD3 mAb1 IL-2 (mean6 SD in
patients with CHH vs controls, 6.5 6 4.6 vs 2.1 6 1.4; P < .05).Correction of T-cell proliferation after
hematopoietic cell transplantation
Patients with CHH and severe immunodeficiency may require
hematopoietic cell transplantation (HCT), and this treatment
often allows prolonged survival with immune reconstitution.5,6
We have shown that RMRP mutations cause abnormal progres-
sion along the cell cycle and defective T-cell proliferation after
stimulation. Because of severe infections, EBV-related lympho-
proliferation, and chronic lung disease, patient 17 received
HCT from his HLA-phenotypically identical father afterreduced-intensity conditioning with fludarabine 150 mg/m2, mel-
phalan 140 mg/m2, and alemtuzumab 1 mg/kg. This treatment re-
sulted in mixed/split chimerism, with 90% donor T cells and 1%
donor myeloid cells, respectively, at 11 months after HCT. We
compared the ability of the patient’s T lymphocytes to undergo
multiple rounds of cell division in response to in vitro stimulation
with anti-CD31 IL-2 before and after HCT (Fig 7). As expected,
before HCT, most of the patient’s CD31 T cells failed to divide or
underwent a single round of proliferation; in contrast, after HCT,
the majority of the cells underwent multiple rounds of cell divi-
sion. These results confirm the cell-intrinsic role of RMRP for
normal T-lymphocyte proliferation.DISCUSSION
Significant variability in the clinical phenotype has been
reported in patients with RMRP mutations. There is some evi-
dence that the type and level of RMRP functional impairment
may correlate with the severity of the clinical spectrum. In par-
ticular, mutations that affect ribosomal RNA cleavage and ribo-
somal assembly are associated with more severe bone dysplasia,
whereas mutations that reduce mRNA cleavage have a more
significant impact on cell cycle regulation and are associated
FIG 5. Cell cycle analysis. Left, Representative examples of cell cycle analysis in control-derived or patient-
derived PBMCs on in vitro stimulation with anti-CD3 (top) or anti-CD31 IL-2 (bottom). Boxes identify cells in
G0/G1 (bromodeoxyuridine [BrdU]27-AAD2), S (BrdU1 7-AAD2/1), and G2/M (BrdU2 7-AAD1) phases of the
cell cycle. The proportion of cells within each of these is annotated. Right, Proportion of PBMCs in G0-G1, S,
and G2/M phases on in vitro culture with anti-CD3 (top) or anti-CD3 1 IL-2 (bottom). Individual symbols
identify single subjects. In each diagram, the horizontal bar represents the mean value. *P < .05.
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malities and cancer.10 Although imprecise, this reported
genotype-phenotype correlation may contribute to significant
variability in the degree of immunodeficiency among patients
with CHH.2-6,16,18 The majority of the patients included in
this study belonged to an Amish population and were homozy-
gous for the g.A70>G mutation. The observation that in vitro–
activated lymphocytes from the patients’ cohort showed
accumulation of cells in the G2/M phase and decreased propor-
tions of cells in the S phase, associated with impaired prolifer-
ation, is consistent with the demonstration that transient
transfection of normal human fibroblasts with the g.A70>G
RMRP mutant construct causes very severe impairment of
cyclin B2 mRNA cleavage.10
Our data indicate that RMRPmutations have a drastic effect on
lymphocyte maturation and function, and that they interfere with
thymic generation of T lymphocytes. This is not unexpected, be-
cause thymic generation of T lymphocytes requires robust prolif-
eration of thymocyte progenitors. Consistent with a potential role
of RMRP in supporting thymopoiesis, we and others have re-
ported profound abnormalities of thymic architecture in some pa-
tients with RMRP mutations.4,14 Furthermore, we previously
reported low to undetectable levels of T-cell receptor excision
circles (another marker to assess de novo thymic generation ofT lymphocytes) in 6 of 7 patients with CHH3; however, all 7
of these patients had significant clinical features suggestive of
CID. In this article, we demonstrate that a low number of RTEs
may also be seen in patients with CHHwithout significant clinical
immunodeficiency. Along with defects in cell cycle progression
and increased apoptosis, these data suggest that at least certain
RMRP mutations are consistently associated with severe cellular
immunodeficiency. It will be important to perform similar studies
in a larger cohort of patients with different mutations to verify
whether RMRP mutations known to interfere with cyclin B2
mRNA processing and cell cycle progression consistently cause
abnormalities of lymphocyte function.
Our results also imply that in contrast with T-cell maturation,
B-cell maturation was less affected by RMRP mutations. B-cell
function was not formally addressed in the current article; how-
ever, we collected data on serum immunoglobulins in 14 of the
18 patients with CHH. With the exception of the patients with
CHH and CID, all patients with CHH tested had normal immuno-
globulin levels. Nine of them were evaluated for tetanus-toxoid
specific antibodies, and 7 had protective (>0.15 IU/mL) titers. Pa-
tient 16 was also immunized with bacteriophage ØX174 and
showed a clearly diminished IgG response suggestive of a func-
tional TH-cell defect reminiscent of patients with CD40 ligand
gene (CD40LG) mutations.
FIG 6. Analysis of apoptosis and cell death. Left, Representative example of fluorescence-activated cell sort-
ing plots after staining of PBMCs for AnnV and 7-AAD in healthy controls and patients with CHH on in vitro
stimulation with anti-CD3 (top) or anti-CD3 1 IL-2 (bottom). Right, Proportion of early apoptotic
(AnnV17-AAD-) and late apoptotic/necrotic (AnnV17-AAD1) PBMCs on in vitro culture with anti-CD3 (top)
or anti-CD3 1 IL-2 (bottom). Individual symbols identify single subjects. In each diagram, the horizontal
bar represents the mean value. *P < .05.
FIG 7. Correction of T-cell proliferation defect after HCT in a patient with
CHH. The proportion of T lymphocytes undergoing 0, 1, 2 or >2 rounds of
proliferation (as indicated by CFSE dilution) after 72 hours of in vitro culture
with anti-CD31 IL-2 is shown for patient 17 before (black bars) or 11months
after (white bars) HCT from his HLA phenotypically identical father. Tx,
Transplantation.
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malities and increased apoptosis observed in our series of
patients. In particular, CHH belongs to a family of diseases,
collectively called ribosomopathies, in which well defined com-
ponents of the ribosome RNA/protein complex are defective.9These diseases mostly affect the hematopoietic lineage. Evidence
from animalmodels indicates that when ribosomal function is dis-
turbed, the levels of master regulator p53 are increased, because
the p53 ubiquitin ligase murine double minute 2 binds to free
ribosomal proteins.19 Increased p53 is associated with cell cycle
arrest and apoptosis.20 The possibility that p53 levels are
increased in CHH and may contribute to the immunodeficiency
remains to be investigated.
Finally, we have confirmed significant heterogeneity of the
CHH clinical phenotype (including variable degree of immu-
nodeficiency), even among patients who share the same RMRP
genetic defect. Given the large number of patients from the
same Amish community, there are limitations to the genetic var-
iability seen in the present cohort. The basis for heterogeneity of
the clinical phenotype of CHH remains unknown, because it
cannot be easily attributed to either genetic or environmental
factors.
In summary, we show that in CHH, despite individual varia-
bility, there is a clear defect in the thymic generation of T
lymphocytes and in peripheral T-cell proliferation, cell cycle
control, and activation-induced cell death. These data provide a
common ground for understanding the functional basis of the
underlying immunodeficiency in CHH.
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phocyte cell cycle control, survival, and proliferation likely con-
tribute to the increased frequency of severe infections in
patients with CHH.REFERENCES
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